UCB in Washington DC: Bio, FDA, NIH with the support of HRH Prince Philippe of Belgium
Posted by
15-Jul-2011
UCB in Washington: biotech, networking and royalty
If you want an idea of how big the annual BIO event has become, try these numbers on for size: 15,626 industry leaders from 65 countries attended; and the BIO Business Forum hosted a record breaking 21,183 partnering meetings between 2,410 companies!
That’s what makes it the place to be for exchanging ideas with scientists, industry and policymakers – or anyone else keen on using biotechnology to improve the lives of patients.
The BIO conference – or the Bio International Convention to give it its full title – is organised by the Biotechnology Industry Organization in the U.S. and always draws a huge crowd.
The conference was high on the itinerary of UCB CEO Roch Doliveux during his fruitful visit to Washington D.C. recently where he met some of the most influential health care leaders in the U.S. The UCB team had joined a Belgian economic mission, led by HRH Prince Philippe of Belgium, on a trip to the U.S. capital which took in a series of meetings with key decision-makers.
Mr Doliveux had the opportunity to meet with Kathleen Sebelius, U.S. Secretary of Health and Human Services and Margaret Hamburg, Commissioner of the U.S. Food and Drug Administration, to discuss various topics within the biotech sector.
He also participated in a panel discussion at the BIO conference where he emphasised UCB’s open innovation model of partnering on cutting-edge scientific research. The debate was preceded by a keynote speech by NIH Director, Francis Collins. One prime example of this partnership model is the new research alliance signed with Harvard University. The agreement will see stronger links between academic researchers and UCB experts who will collaborate on developing innovative new medicines.
At the BIO event, the UCB team and other members of the Belgian business delegation took the opportunity to meet leaders from industry, government and academia. The conference looked at how biotechnology can help solve some of the world’s most pressing problems - including fighting disease, reducing health care costs and combating hunger.
It was a busy trip that helped UCB continue to expand its growing network of partners and further cemented the company’s place on the international biotech calendar.
And we can look forward to doing it all again next year in Boston...
If you want an idea of how big the annual BIO event has become, try these numbers on for size: 15,626 industry leaders from 65 countries attended; and the BIO Business Forum hosted a record breaking 21,183 partnering meetings between 2,410 companies!
That’s what makes it the place to be for exchanging ideas with scientists, industry and policymakers – or anyone else keen on using biotechnology to improve the lives of patients.
The BIO conference – or the Bio International Convention to give it its full title – is organised by the Biotechnology Industry Organization in the U.S. and always draws a huge crowd.
The conference was high on the itinerary of UCB CEO Roch Doliveux during his fruitful visit to Washington D.C. recently where he met some of the most influential health care leaders in the U.S. The UCB team had joined a Belgian economic mission, led by HRH Prince Philippe of Belgium, on a trip to the U.S. capital which took in a series of meetings with key decision-makers.
Mr Doliveux had the opportunity to meet with Kathleen Sebelius, U.S. Secretary of Health and Human Services and Margaret Hamburg, Commissioner of the U.S. Food and Drug Administration, to discuss various topics within the biotech sector.
He also participated in a panel discussion at the BIO conference where he emphasised UCB’s open innovation model of partnering on cutting-edge scientific research. The debate was preceded by a keynote speech by NIH Director, Francis Collins. One prime example of this partnership model is the new research alliance signed with Harvard University. The agreement will see stronger links between academic researchers and UCB experts who will collaborate on developing innovative new medicines.
At the BIO event, the UCB team and other members of the Belgian business delegation took the opportunity to meet leaders from industry, government and academia. The conference looked at how biotechnology can help solve some of the world’s most pressing problems - including fighting disease, reducing health care costs and combating hunger.
It was a busy trip that helped UCB continue to expand its growing network of partners and further cemented the company’s place on the international biotech calendar.
And we can look forward to doing it all again next year in Boston...
Leave a Comment